Pulmonary Edema Medications: From Diuretics to Inotropes

Pulmonary edema, the dangerous accumulation of fluid in the lungs, is treated with a surprisingly varied toolkit of medications depending on what is driving the fluid buildup. For the most common scenario, acute heart failure pushing fluid into the lungs, intravenous loop diuretics like furosemide remain the cornerstone, often paired with vasodilators such as nitroglycerin to take pressure off the heart. But the drug list diverges sharply from there. High-altitude pulmonary edema calls for calcium channel blockers. Sepsis-related lung flooding may involve corticosteroids. And some long-trusted drugs, particularly morphine, have been falling out of favor as evidence mounts against them.

Loop Diuretics as the First-Line Drug

When someone arrives in an emergency department struggling to breathe because of fluid-overloaded lungs, the near-universal first medication is an intravenous loop diuretic, most commonly furosemide. These drugs act on the kidneys to force out sodium and water, reducing the total volume of fluid in circulation and thereby lowering the pressure that is pushing fluid into the lung tissue. The effect can begin within minutes of an IV dose.

Furosemide also has a direct vascular effect that kicks in before the kidneys even respond. Research on healthy volunteers showed that furosemide produces dose-dependent vein relaxation, reaching roughly 70% venorelaxation at higher doses, and systemic administration increased hand vein distensibility by about 45% within eight minutes. This venodilation appears to be driven by local prostaglandin production in the vessel walls rather than by nitric oxide pathways.

1PubMed. Direct vascular effects of furosemide in humans

That early venous pooling effect is clinically meaningful because it reduces the amount of blood returning to the heart before the kidneys have had time to excrete any fluid. For a patient drowning in their own lung fluid, those first few minutes matter enormously.

Vasodilators and Nitroglycerin for Acute Hypertensive Crises

A specific and dramatic presentation of pulmonary edema occurs when a massive sympathetic nervous system surge drives blood pressure to dangerously high levels, flooding the lungs in minutes. Emergency physicians sometimes refer to this as sympathetic crashing acute pulmonary edema, or SCAPE. Patients arrive in severe respiratory distress with oxygen levels plummeting and blood pressures often well above 200 mmHg systolic.

For these patients, diuretics alone are not enough, and the more urgent need is to bring down the afterload, the resistance the heart is pumping against. High-dose nitroglycerin has emerged as a go-to treatment in this setting. In a case series of three SCAPE patients treated with high-dose nitroglycerin alongside bilevel positive airway pressure ventilation, all three improved rapidly and none required intubation or intensive care admission.

2PubMed Central. Treating acute hypertensive cardiogenic pulmonary edema with high-dose nitroglycerin

The logic is straightforward: nitroglycerin dilates both veins and arteries, reducing the blood returning to the heart and the resistance the heart faces when it contracts. Both actions rapidly lower the pressure gradient forcing fluid across the lung capillaries. In many emergency departments, the protocol involves giving repeated boluses of nitroglycerin rather than a slow drip, because the goal is rapid pressure reduction in a patient who may be minutes from needing a breathing tube.

A prehospital study tested a protocol that combined nitrates with non-invasive ventilation started by paramedics before hospital arrival. The intervention was associated with a large reduction in seven-day and thirty-day mortality compared to standard prehospital treatment.

3medRxiv. Safety and efficacy of a prehospital initiated protocol of nitrates plus non-invasive ventilation on prehospital and Emergency Department outcomes for acute cardiogenic pulmonary oedema

Why Morphine Fell Out of Favor

For decades, morphine was a staple in the emergency treatment of acute pulmonary edema. The rationale seemed sound: it reduces anxiety and the sensation of breathlessness, lowers sympathetic drive, and was thought to cause venodilation that would help offload the heart. Many older textbooks list morphine as part of the standard acute pulmonary edema cocktail. That thinking has changed substantially.

A systematic review and meta-analysis examining morphine use in acute cardiogenic pulmonary edema found that it was associated with more than double the odds of in-hospital death. Patients who received morphine were also roughly six times more likely to need invasive mechanical ventilation, nearly twice as likely to need non-invasive ventilation, and about three times more likely to require vasopressor or inotrope support.

4PubMed Central. Impact of morphine use in acute cardiogenic pulmonary oedema on mortality outcomes: a systematic review and meta-analysis

These are observational findings, which means sicker patients may have been more likely to receive morphine in the first place. But a randomized trial comparing morphine to midazolam in acute cardiogenic pulmonary edema reinforced the concern. While in-hospital mortality did not differ significantly between the two groups, serious adverse events were more than twice as common in the morphine arm compared to midazolam. The trial was small, so it could not definitively settle the mortality question, but the pattern of more complications with morphine was consistent with the observational data.

5PubMed. Midazolam versus morphine in acute cardiogenic pulmonary oedema: results of a multicentre, open-label, randomized controlled trial

The most plausible explanation is that morphine’s respiratory depressant effects are particularly dangerous in patients who are already struggling to breathe. It can also cause hypotension and nausea, both of which complicate treatment. Many current guidelines have downgraded morphine from routine use to a last-resort anxiolytic when other options are unavailable.

Inotropes and Vasopressors When the Heart Is Failing

Not all pulmonary edema patients have high blood pressure. Some arrive in cardiogenic shock, where the heart is so weakened that blood pressure has dropped dangerously low even as the lungs fill with fluid. Diuretics and vasodilators can make things worse in this scenario by further lowering blood pressure. These patients need medications that either strengthen the heart’s contractions or tighten the blood vessels to maintain perfusion to vital organs, sometimes both.

European cardiology guidelines and the SOAP II trial have positioned norepinephrine as the first-line vasopressor for cardiogenic shock patients with low blood pressure and vasodilation. For patients needing high vasopressor doses or those with unstable heart rhythms, adding vasopressin can be safer than pushing norepinephrine higher. Inotropes, drugs that strengthen the heart’s squeeze, are recommended for short-term use in low-output states. Dobutamine is the standard choice for isolated left ventricular failure, while milrinone or levosimendan are preferred when pulmonary pressures are elevated or the right ventricle is struggling. Milrinone and levosimendan also work in patients already on beta-blockers, since their mechanism bypasses beta-adrenergic receptors entirely.

6Revista Portuguesa de Cardiologia (English edition). Cardiogenic shock: Inotropes and vasopressors

These medications are high-stakes interventions used in intensive care settings with continuous monitoring. The choice between them requires real-time assessment of whether the dominant problem is a weak heart, collapsed blood vessels, or both.

Overcoming Diuretic Resistance

A frustrating reality in treating heart failure-related pulmonary edema is that loop diuretics sometimes stop working well enough. The kidneys adapt to chronic diuretic exposure by increasing sodium reabsorption at points downstream from where loop diuretics act. This phenomenon, called diuretic resistance, means that some patients continue to accumulate fluid despite escalating furosemide doses.

The classic strategy is sequential nephron blockade, essentially adding a second diuretic that acts on a different part of the kidney’s filtering system. Thiazide-type diuretics such as metolazone and chlorothiazide are the standard add-on agents, though which one works best has been uncertain.

7PubMed. A Systematic Review and Meta-Analysis of Metolazone Compared to Chlorothiazide for Treatment of Acute Decompensated Heart Failure

The 3T trial directly compared three approaches in diuretic-resistant acute heart failure: adding metolazone, adding intravenous chlorothiazide, or adding tolvaptan, a vasopressin receptor blocker that causes the kidneys to excrete water without sodium. All three strategies significantly improved diuretic response, with no clear winner among them. Patients lost roughly four to six kilograms of fluid weight over 48 hours regardless of which agent was added, and urine output was similarly boosted across all three groups.

8PubMed Central. Diuretic Strategies for Loop Diuretic Resistance in Acute Heart Failure: The 3T Trial

The practical upshot is that metolazone, which is inexpensive and given by mouth, works about as well as the more expensive alternatives. That has made it the default add-on in many hospitals, though the choice can depend on whether a patient can take oral medication and how urgently fluid removal is needed.

SGLT2 Inhibitors and Long-Term Congestion Prevention

A newer class of medications has changed how clinicians think about preventing recurrent pulmonary edema in heart failure patients. SGLT2 inhibitors like dapagliflozin and empagliflozin were originally diabetes drugs, but they turned out to have striking benefits for heart failure regardless of whether the patient has diabetes. They work by blocking glucose and sodium reabsorption in the kidney, producing a mild osmotic diuresis. Beyond that direct fluid effect, they appear to improve how the heart muscle uses energy, shifting it toward more efficient fuel sources.

9Clinical Kidney Journal. Decongestion in patients with advanced chronic kidney disease coexisting with heart failure

Whether adding an SGLT2 inhibitor during an acute hospitalization helps beyond standard diuretics is still being worked out. One trial found that adding dapagliflozin to intravenous loop diuretics did not significantly change most congestion markers, but it did produce a meaningful reduction in lung ultrasound B-lines, a direct measure of lung water, both at discharge and at one month.

10ESC Heart Failure. Pulmonary Congestion Relief By Adding Dapagliflozin to Intravenous Loop Diuretic in Acute Heart Failure Patients

Mineralocorticoid receptor antagonists like spironolactone and eplerenone are also widely used alongside loop diuretics for preventing congestion from recurring. Both high-dose and low-dose spironolactone appear equally effective at reducing clinical congestion scores, breathlessness, and net fluid output.

11Clinical Kidney Journal. Decongestion in patients with advanced chronic kidney disease coexisting with heart failure

High-Altitude Pulmonary Edema

Pulmonary edema at high altitude has nothing to do with heart failure. It happens when low oxygen levels trigger an exaggerated constriction of the lung’s blood vessels, raising pulmonary artery pressure so high that fluid leaks out of the capillaries and into the air sacs. The most important treatment is descent, but when descent is delayed or impossible, medications can be lifesaving.

Nifedipine, a calcium channel blocker, has been the standard drug for both prevention and treatment. A landmark trial in the New England Journal of Medicine showed that prophylactic nifedipine effectively lowered pulmonary artery pressure and prevented high-altitude pulmonary edema in people with a known history of susceptibility.

12PubMed. Prevention of high-altitude pulmonary edema by nifedipine

Current protocols typically use nifedipine extended-release at 20 milligrams every eight hours or 30 milligrams every 12 hours. Phosphodiesterase inhibitors like sildenafil and tadalafil have also shown good results and may cause less systemic blood pressure drop than nifedipine, which matters when a person is already stressed and dehydrated at altitude.

13PubMed Central. High Altitude Pulmonary Edema

Ironically, nifedipine appeared among the top drugs associated with drug-induced pulmonary edema in a pharmacovigilance analysis, though the context there involves systemic use in very different patient populations than altitude medicine.

Non-Cardiogenic Edema and Corticosteroids

When pulmonary edema results from lung injury itself rather than heart failure, the treatment changes entirely. Conditions like sepsis, pneumonia, inhalation injury, and trauma can damage the lung’s air-blood barrier directly, letting protein-rich fluid flood the alveoli. Diuretics are less helpful here because the problem is not excess fluid volume but a leaky barrier.

Corticosteroids have a complicated role in this setting. Prolonged courses can shorten the time patients spend on mechanical ventilation and in the hospital, and they improve oxygenation. These benefits likely come from a combination of anti-inflammatory, antioxidant, and anti-edema effects.

14PubMed Central. Corticosteroids in Acute Lung Injury: The Dilemma Continues

Neurogenic pulmonary edema, triggered by acute brain injury such as stroke, head trauma, or seizure, represents yet another variant. No specific drugs are approved for it. Management is primarily supportive, focused on controlling brain swelling and minimizing the sympathetic storm using agents such as adrenergic blockers or vasodilators as the clinical picture demands.

15PubMed Central. Neurogenic pulmonary edema

Research over the past three decades has clarified how the lung naturally clears edema fluid. Sodium enters the airspace side of lung cells through epithelial sodium channels and is pumped out the other side by sodium-potassium pumps, creating an osmotic gradient that pulls water out of the flooded air sacs. This process can be boosted by cAMP-dependent stimulation through adrenergic receptors and by several independent pathways including glucocorticoids, thyroid hormone, and growth factors.

16Oxford Academic. Resolution of Pulmonary Edema. Thirty Years of Progress

Inhaled Pulmonary Vasodilators

In critical care, inhaled vasodilators offer a unique advantage: they dilate only the blood vessels in well-ventilated parts of the lung, improving the match between airflow and blood flow without dropping systemic blood pressure. Inhaled nitric oxide is the classic agent, and it produces selective pulmonary vasodilation in patients with pulmonary hypertension without the systemic side effects of intravenous vasodilators.

17PubMed Central. Inhaled pulmonary vasodilators: a narrative review

Inhaled epoprostenol, a prostacyclin, achieves similar lung-selective vasodilation at lower cost than nitric oxide. Comparative studies have examined whether combining the two agents produces additive effects, given that they work through different biochemical pathways.

18PubMed Central. Comparison of acute hemodynamic effects of inhaled nitric oxide and inhaled epoprostenol in patients with pulmonary hypertension

These inhaled drugs are not typically used for garden-variety cardiogenic pulmonary edema. Their niche is in patients with severe pulmonary hypertension, right heart failure, or the kind of refractory hypoxemia that comes with acute respiratory distress syndrome, where systemically administered vasodilators would tank blood pressure before meaningfully helping the lungs.

Drug-Induced Pulmonary Edema

Sometimes medications themselves cause pulmonary edema, and the list of offenders is broader than most people realize. A pharmacovigilance study mining the FDA’s adverse event database identified 37 drugs with a signal for drug-induced pulmonary edema. The top five were naloxone (an opioid reversal agent), dasatinib (a cancer drug), nifedipine, anti-thymocyte globulin (an immune suppressant), and pioglitazone (a diabetes drug). All except pioglitazone were confirmed as independent risk factors after adjusting for other variables.

19PubMed Central. Drug-induced pulmonary edema: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System (FAERS)

Among the top 20 drugs by raw case count, several are widely prescribed: amlodipine (a blood pressure drug), fentanyl, methotrexate, pregabalin, and sacubitril/valsartan, which is itself a heart failure medication. The mechanisms vary. Dasatinib is thought to cause pulmonary vascular constriction, naloxone can trigger a sudden sympathetic surge when it reverses opioids, and some cancer drugs damage the lung endothelium directly.

20PubMed Central. Drug-induced pulmonary edema: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System (FAERS)

The treatment in drug-induced cases is usually withdrawal of the offending agent combined with supportive care. Diuretics can help manage the fluid, but the condition will not resolve until the triggering drug is stopped.

Experimental Approaches Targeting the Vascular Barrier

Most current treatments for pulmonary edema work on the consequences of the problem: removing excess fluid, lowering pressure, or supporting the heart. A more fundamental approach would be to seal the leaky blood vessel barrier itself, and several experimental strategies are moving in that direction.

Imatinib, a cancer drug known for treating certain leukemias, has shown promise in animal models. Pretreating mice with imatinib protected against vascular leakage in the lungs, and giving it after the onset of sepsis reduced kidney and lung leakage at 24 hours. The drug works by inhibiting a specific signaling protein involved in pulling apart the connections between endothelial cells that line blood vessels.

21PubMed. Effective treatment of edema and endothelial barrier dysfunction with imatinib

Another experimental agent, FX06, is a peptide derived from fibrin that binds to VE-cadherin, a protein critical for holding endothelial cells together. In laboratory tests using serum from patients with systemic capillary leak syndrome, FX06 both prevented and reversed the excessive permeability. The researchers suggest this approach could extend beyond rare leak syndromes to any condition where vascular barrier breakdown is driving edema.

22PubMed. Unlocking endothelial barrier restoration: FX06 in systemic capillary leak syndrome and beyond

Basic research has also identified several naturally occurring molecules that strengthen the endothelial barrier, including oxidized phospholipids, sphingosine 1-phosphate, prostacyclins, and hepatocyte growth factor, all of which activate pathways that tighten cell-to-cell junctions.

23PubMed Central. Injured lung endothelium: mechanisms of self-repair and agonist-assisted recovery (2017 Grover Conference Series)

None of these barrier-sealing approaches are ready for clinical use yet. But they represent a genuinely different strategy from anything currently available, one that goes after the root cause of non-cardiogenic pulmonary edema rather than managing the downstream consequences. If any of them succeed in human trials, they could change how conditions like sepsis-related lung injury and acute respiratory distress syndrome are treated.